A San Francisco jury has backed Illumina (NASDAQ:ILMN) in a patent infringement lawsuit against Ariosa Diagnostics pertaining to the Harmony non-invasive prenatal test (NIPT). Specifically, the jury found that Ariosa’s previous and current version of the test infringes on two Illumina patents (U.S. Patent Nos. 8,318,430 and 7,955,794) and awarded $26.7M to Illumina for damages.

The jury rejected counterclaims by Ariosa, now owned by Roche (OTCQX:RHHBY), that Illumina breached a supply agreement between the two firms by filing the litigation.

Illumina says it will seek injunctive relief to prohibit Ariosa from marketing its test.

Story from seekingalpha.com

Subscribe To Our Newsletter

Would you like to receive our popular weekly news alerts straight to your inbox? Solely patent focused and only sent once a week means you can guarantee there will be something you are interested in reading instead of clogging up your inbox with junk. Sign up now!

You have Successfully Subscribed!